Global Medical REIT (GMRE) Receives $10.13 Average Price Target from Analysts

Shares of Global Medical REIT (NYSE:GMRE) have been given a consensus recommendation of “Buy” by the six brokerages that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $10.13.

A number of research analysts recently weighed in on the stock. B. Riley dropped their price objective on shares of Global Medical REIT from $10.50 to $10.00 and set a “buy” rating for the company in a report on Thursday, May 10th. Zacks Investment Research upgraded shares of Global Medical REIT from a “hold” rating to a “strong-buy” rating and set a $9.75 price target for the company in a report on Wednesday, May 9th. DA Davidson upgraded shares of Global Medical REIT from a “neutral” rating to a “buy” rating and set a $8.00 price target for the company in a report on Wednesday, March 28th. Finally, Cantor Fitzgerald assumed coverage on shares of Global Medical REIT in a report on Wednesday, March 7th. They set a “buy” rating and a $12.00 price target for the company.

Get Global Medical REIT alerts:

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd acquired a new position in Global Medical REIT during the 1st quarter worth approximately $224,000. Millennium Management LLC boosted its holdings in shares of Global Medical REIT by 370.7% in the 1st quarter. Millennium Management LLC now owns 229,150 shares of the company’s stock valued at $1,593,000 after buying an additional 180,465 shares in the last quarter. A.R.T. Advisors LLC boosted its holdings in shares of Global Medical REIT by 126.4% in the 1st quarter. A.R.T. Advisors LLC now owns 28,130 shares of the company’s stock valued at $195,000 after buying an additional 15,703 shares in the last quarter. GSA Capital Partners LLP boosted its holdings in shares of Global Medical REIT by 329.0% in the 1st quarter. GSA Capital Partners LLP now owns 99,100 shares of the company’s stock valued at $689,000 after buying an additional 76,000 shares in the last quarter. Finally, Stifel Financial Corp boosted its holdings in shares of Global Medical REIT by 29.2% in the 1st quarter. Stifel Financial Corp now owns 189,956 shares of the company’s stock valued at $1,319,000 after buying an additional 42,958 shares in the last quarter. Institutional investors own 38.80% of the company’s stock.

Shares of Global Medical REIT traded up $0.33, reaching $9.53, during trading on Tuesday, Marketbeat reports. The company’s stock had a trading volume of 548,220 shares, compared to its average volume of 102,395. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.17 and a current ratio of 0.17. The stock has a market capitalization of $199.00 million, a P/E ratio of 17.65, a price-to-earnings-growth ratio of 1.24 and a beta of 0.50. Global Medical REIT has a 1-year low of $6.34 and a 1-year high of $10.25.

Global Medical REIT (NYSE:GMRE) last announced its quarterly earnings data on Tuesday, May 8th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The business had revenue of $11.56 million during the quarter, compared to analyst estimates of $11.50 million. Global Medical REIT had a net margin of 7.75% and a return on equity of 1.61%. research analysts forecast that Global Medical REIT will post 0.82 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 11th. Shareholders of record on Tuesday, June 26th will be issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 8.39%. The ex-dividend date of this dividend is Monday, June 25th. Global Medical REIT’s dividend payout ratio (DPR) is presently 148.15%.

About Global Medical REIT

Global Medical REIT Inc is a Maryland corporation engaged primarily in the acquisition of licensed, state-of-the-art, purpose-built healthcare facilities and the leasing of these facilities to strong clinical operators with leading market share. The Company's management team has significant healthcare, real estate and public real estate investment trust, or REIT, experience and has long-established relationships with a wide range of healthcare providers.

Worsening Nafta Outlook Has Traders Betting Bank of Canada Will Turn Dovish

LISTEN TO ARTICLE 2:01 SHARE THIS ARTICLE Facebook Twitter LinkedIn Email

Short-end traders are piling into wagers the Bank of Canada will turn dovish as erupting trade tensions shake market confidence in the outlook for future interest-rate increases.

The gap between September 2018 and December 2018 bankers’ acceptance futures narrowed to 14.5 basis points Tuesday amid record two-day volumes in the spread. Market participants are now pricing in just 41 basis points of additional policy tightening by year-end, down from more than 60 basis points as recently as last month. The Canadian dollar has declined in tandem, sliding 2.5 percent against the greenback since the start of June.

Expectations for future BOC rate hikes are waning as the outlook for North American Free Trade Agreement negotiations grows increasingly fraught. President Donald Trump said again Tuesday that the U.S. has been “treated horribly” by its northern neighbor. Meanwhile, U.S.-China trade relations are faring no better, with Beijing threatening retaliation should Washington follow through on a pledge to impose duties on another $200 billion of Chinese goods. Anxiety over escalating trade tensions could slow the BOC’s tightening push, according to Canadian Imperial Bank of Commerce.

#lazy-img-328698095:before{padding-top:56.25%;}

“The decline in market-implied odds for July portend to concerns surrounding the global trade outlook,” said CIBC FX and macro strategist Bipan Rai, who still expects the BOC to hike next month. “As of now, you could talk us into a rate hike later this year, but that’s becoming a more difficult decision with trade risk.”

The odds of a rate increase at the BOC’s July 11 meeting have dwindled to about 65 percent, according to overnight index swap pricing, from roughly 80 percent in the aftermath of the bank’s May 30 meeting.

The Canadian dollar has tumbled more than 5 percent versus the greenback in 2018, making the loonie the third-worst performing Group-of-10 currency in the span. It weakened to C$1.3292 Tuesday as Trump singled out dairy, energy and timber as sectors where Canada is taking advantage of the U.S.

Top Gold Stocks To Watch For 2019

tags:PACB,KOP,DXPE,

401(k) Savers May Have to Fund Trump��s Corporate Tax Cut

Texas Judge Denies Emergency Request to Block DOL Fiduciary Rule

Did Warren Overreach in Blasting Annuity Sales Perks?

A regulatory panel has decided that barred broker and current radio host Dawn Bennett must pay a client over $1 million in compensation and fees for investments in SPDR Gold ETFs.

The Miami-based Financial Industry Regulatory Authority panel ruled that Bennett, Western International Securities and Bennett Group Financial Services are required to give Steven Santagati, a dating counselor, about $764,000 in compensation and nearly $280,000 to cover legal and related fees.

The host of a radio show, "Financial Myth Busting With Dawn Bennett," and her firm are accused of inflating their...

You are signed up!

ThinkAdvisor's TechCenter is an educational resource designed to give you a competitive edge by keeping you abreast of new tech innovations and need-to-know information that can be applied to your business. Resources White Paper: Creating a Successful Transition

It's not when you retire. It's how you retire.

Top Gold Stocks To Watch For 2019: Pacific Biosciences of California Inc.(PACB)

Advisors' Opinion:

• [By Paul Ausick]

  Pacific Biosciences of California Inc. (NASDAQ: PACB) slipped about 5.6% to post a new 52-week low of $2.52 Tuesday after closing at $2.67 on Friday. Volume of about 910,000 was about 10% above the daily average. The company had no specific news.

• [By Lisa Levin] Gainers Pacific Biosciences of California, Inc. (NASDAQ: PACB) rose 11.4 percent to $2.93 in pre-market trading. Check-Cap Ltd. (NASDAQ: CHEK) shares rose 6.3 percent to $4.76 in pre-market trading as the company announced the publication of CE Mark multicenter clinical study results on C-Scan® in Gut. Acacia Communications, Inc. (NASDAQ: ACIA) rose 6 percent to $ 35.20 in pre-market trading. Cellect Biotechnology Ltd. (NASDAQ: APOP) rose 6 percent to $7.60 in pre-market trading. Hexindai Inc. (NASDAQ: HX) rose 5.7 percent to $12.70 in pre-market trading. MoSys, Inc. (NASDAQ: MOSY) shares rose 5.3 percent to $2.07 in pre-market trading. Micron Technology, Inc. (NASDAQ: MU) rose 5 percent to $58.20 in pre-market trading after reporting a $10 billion buyback plan. Golden Ocean Group Limited (NASDAQ: GOGL) rose 4.1 percent to $8.63 in pre-market trading. MorphoSys AG (NASDAQ: MOR) rose 3.5 percent to $26.99 in pre-market trading. Cyren Ltd (NASDAQ: CYRN) shares rose 3.4 percent to $2.90 in pre-market trading. after reporting Q1 results. Box, Inc. (NYSE: BOX) rose 3.4 percent to $28.76 in pre-market trading. Kohl's Corporation (NYSE: KSS) shares rose 3.3 percent to $67.60 in the pre-market trading session after the company reported upbeat quarterly earnings. Micro Focus International plc (NYSE: MFGP) shares rose 3.1 percent to $18.40 in pre-market trading.

   

• [By Joseph Griffin]

  ValuEngine upgraded shares of Pacific Biosciences of California (NASDAQ:PACB) from a sell rating to a hold rating in a research report report published on Saturday morning.

• [By Cory Renauer]

  Shares of Pacific Biosciences of California�(NASDAQ:PACB),�a genetic-sequencing system manufacturer, rose 11% on Thursday and continued their climb into Friday's session. Investors appear pleased with new productivity-boosting tools to be featured at this week's meeting of the American Society for Microbiology.

Top Gold Stocks To Watch For 2019: Koppers Holdings Inc.(KOP)

Advisors' Opinion:

• [By Stephan Byrd]

  Koppers (NYSE:KOP) was upgraded by equities research analysts at TheStreet from a “c” rating to a “b-” rating in a report released on Friday.

• [By Logan Wallace]

  Koppers (NYSE:KOP) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.

Top Gold Stocks To Watch For 2019: DXP Enterprises Inc.(DXPE)

Advisors' Opinion:

• [By Joseph Griffin]

  News stories about DXP Enterprises (NASDAQ:DXPE) have been trending somewhat positive on Saturday, according to Accern. Accern scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. DXP Enterprises earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave news headlines about the industrial products company an impact score of 46.1699723331071 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

• [By Joseph Griffin]

  Get a free copy of the Zacks research report on DXP Enterprises (DXPE)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Logan Wallace]

  American Century Companies Inc. decreased its position in DXP Enterprises, Inc. (NASDAQ:DXPE) by 63.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 266,785 shares of the industrial products company’s stock after selling 454,667 shares during the quarter. American Century Companies Inc. owned approximately 1.54% of DXP Enterprises worth $10,391,000 at the end of the most recent reporting period.

Shares of J.Jill Pop 20% After Topping Analysts' Estimates During the First Quarter

What happened

Shares of J.Jill, Inc. (NYSE:JILL), an omnichannel premier retailer of women's apparel, are popping 20% higher as of 10:40 a.m. EDT Thursday, after the company announced a strong first quarter.

So what

Total net sales during the first quarter increased 9.3% to $181.5 million, partially driven by a 2.3% increase in comparable sales. Adjusted earnings per share checked in at $0.29, above the prior year's $0.24 per share. Both results topped analysts' estimates calling for $0.19 adjusted earnings per share on revenue of $159.7 million. J.Jill still has a strong e-commerce story with its direct to consumer net sales generating 40.5% of total net sales during the first quarter.

Image source: Getty Images.

"I am excited to have joined J.Jill at an important time in our company's history as we plan our next phase of growth. The first quarter underscores we have work to do and we have indicators of improvement. We experienced positive comps in our retail stores. We also saw improved results from our e-commerce channel. We remain focused on initiatives to improve our overall performance and get us on track to deliver at a consistent level that is expected," said J.Jill CEO Linda Heasley, in a press release.

Now what

While the stock popping 20% Thursday morning is welcomed by investors -- J.Jill's stock has a history of popping and dropping after quarterly results -- there's still work to be done at J.Jill considering the stock is still down 34% over the past 12 months. Further, management expects a slightly slower second quarter due to calendar shifts that pulled some sales from the second quarter into the first quarter. Investors would be wise to keep an eye on comparable store sales; management expects comparable sales to check in flat to a positive low single digit gain.